These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39664396)

  • 1. Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.
    Liguori L; Giorgio G; Polcaro G; Pagliara V; Malandrino D; Perri F; Cascella M; Ottaiano A; Conti V; Servetto A; Bianco R; Pepe S; Sabbatino F
    Front Immunol; 2024; 15():1419544. PubMed ID: 39664396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
    Liu M; Li Q; Meng X; Cui Y; Sun W; Wang H; Gao Q
    Medicine (Baltimore); 2024 Dec; 103(49):e40569. PubMed ID: 39654181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China.
    Li H; Yuan Y; Xu Q; Liang G; Hu Z; Li X; Zhang W; Lei H
    Front Immunol; 2024; 15():1487078. PubMed ID: 39635526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
    Miller S; Jiang R; Schipper M; Fritsche LG; Strohbehn G; Wallace B; Brinzevich D; Falvello V; McMahon BH; Zamora-Resendiz R; Ramnath N; Dai X; Sankar K; Edwards DM; Allen SG; Yoo S; Crivelli S; Green MD; Bryant AK
    Lancet Oncol; 2024 Dec; 25(12):1666-1676. PubMed ID: 39551068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D
    Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review.
    O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H
    Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).
    Landre T; Chouaïd C; Sadaoui N; Bouharati D; Taleb C
    J Chemother; 2024 Dec; 36(8):675-681. PubMed ID: 38303601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer.
    Sako C; Duan C; Maresca K; Kent S; Schmidt TG; Aerts HJWL; Parikh RB; Simon GR; Jordan P
    JCO Clin Cancer Inform; 2024 Dec; 8():e2400133. PubMed ID: 39671539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.